Understanding the role for DNA methylation in tumorigenesis has evolved from de®ning the location and extent of methylation in a variety of cancer-related genes to clarifying the functional and site-speci®c eects of aberrant methylation on gene expression. Our objectives were to characterize the functional eects of DNA methylation in the BRCA1 promoter and to clarify the functional status of the BRCA1 CRE (cAMP response element) motif. Luciferase reporter assays con®rm that an intact CRE is important for BRCA1 expression in transient transfections. Luciferase activities were decreased in constructs where the CRE recognition sequence was altered and when constructs were methylated in vitro. Gel mobility shift and competition assays identi®ed a DNA-protein complex recognizing the CRE motif that we were able to supershift using CREBspeci®c antibody. Furthermore this CRE is methylation sensitive, and we localized this methylation eect to a CpG dinucleotide within the BRCA1 CRE motif. The consequences of aberrant DNA methylation at speci®c transcription factor motifs, along with the multiple mutational events that can occur in a variety of essential genes such as BRCA1, paint a complex picture where both genetic and epigenetic changes contribute to tumour formation. Oncogene (2001) 20, 5331 ± 5340.
Introduction
Understanding the role for DNA methylation in tumorigenesis has evolved from establishing the occurrence of methylation in cancer-related genes to clarifying the functional eects of aberrant methylation within gene regulatory regions. These regions are usually associated with unmethylated CpG-rich islands, and as such exist as potential targets for methylationbased transcriptional repression (Issa et al., , 1996a Lapidus et al., 1996; Ottaviano et al., 1994; Ohtani-Fujita et al., 1993) .
Alterations in promoter methylation patterns have been identi®ed as novel events in a proportion of sporadic cancers, thereby inferring an inhibitory role for methylation on gene expression (Mancini et al., , 1999 Ferguson et al., 1998; Gowen et al., 1998; Scully et al., 1997; Merlo et al., 1995; Herman et al., 1994; Miki et al., 1994; Meyer and Habener, 1993) . This process of gene silencing has been shown to interfere with the binding of the transcriptional machinery to the promoter template (Okuse et al., 1997; Ohtani-Fujita et al., 1993) . For example, sitespeci®c methylation at CpGs within CRE and RBF-1 regulatory elements in the RB1 gene impedes factor binding and dramatically reduces RB1 expression (Hwu et al., 1997; Ottaviano et al., 1994) . Such results suggest a site-speci®c eect of methylation on transcriptional inactivation that may be complemented by changes in histone acetylation pathways, thus altering chromatin conformation and repressing transcription (Razin 1998; Meyer and Habener, 1993; Sakai et al., 1991) .
Regional hypermethylation within the BRCA1 regulatory region has been reported by our group and by others in sporadic breast carcinomas (Rice et al., 1998 Mancini et al., 1998; Dobrovic and Simpfendorfer, 1997) and in sporadic ovarian carcinomas (Baldwin et al., 2000) . Furthermore, decreased BRCA1 expression has been correlated with aberrant cytosine methylation, histone hypoacetylation and chromatin condensation involving a critical BRCA1 promoter subregion Rice et al., 1998) . In a previous report our group found evidence of allele-speci®c DNA methylation in sporadic breast and ovarian tumours in the regulatory region anking BRCA1 exon 1A (Mancini et al., 1998) . We demonstrated that methylation in the BRCA1 promoter within sporadic breast and ovarian tumours appeared to have an eect at several putative transcription factor binding sites including a cAMP response element (CRE; Mancini et al., 1998) . This CRE is sensitive to site-speci®c CpG methylation in gel mobility shift assays (Mancini et al., 1998) . Xu et al. (1997) localized several cis-control elements within a 267 bp BRCA1 minimal promoter and determined that the basic promoter activities of BRCA1 are modulated by various transcription elements including putative Sp1 and CRE motifs. Thakur and Croce (1999) further delineated a 36 bp BRCA1 positive regulatory region (PRR) and Suen and Goss (1999) de®ned a minimal 56 bp fragment within the BRCA1-NBR2 intergenic region which includes the 36 bp sequence de®ned by the Croce group, and which retains bi-directional promoter activity. The overlapping BRCA1 promoter regions described in these reports share common CRE and¯anking sequences although both groups have been unable to con®rm the functionality of this CRE or to identify the presence of CREB protein in BRCA1 CRE-protein complexes (Thakur and Croce, 1999; Suen and Goss, 1999) .
The primary objectives of our present report were to characterize the functional eects of DNA methylation in the BRCA1 promoter using luciferase reporter constructs expressed in an MCF-7 breast carcinoma cell line. Methylation of these constructs with SssI methylase in vitro greatly decreased expression of the reporter genes. Our data support the hypothesis that aberrant promoter methylation exerts a suppressive eect on BRCA1 expression. This methylation eect includes, but is not apparently restricted to the CRE. The consequences of aberrant DNA methylation at speci®c transcription factor motifs such as the CRE, along with the multiple mutational events that can occur in a variety of essential genes such as BRCA1, support roles for genetic and epigenetic changes in tumour formation.
Results

Functional analysis of the BRCA1 promoter
Luciferase reporter constructs were generated by inserting overlapping subregions of the BRCA1 promoter into the pGL3-Basic vector (Figure 1 ). We focused on regions of the BRCA1 promoter previously demonstrated to be responsible for high BRCA1 expression. In particular, a 602 bp subregion (SCV; spanning 7458 to +145) was used that was shown to possess strong promoter activity and which includes a putative CRE site at position 7173 (Maesawa et al., 1996) . The other plasmids utilized in this study possess smaller regions of the BRCA1 promoter. Table 1 shows results from two separate luciferase experiments each of which was performed in triplicate. Background luciferase activities (relative light units /mg protein: RLU/mg protein) were determined for the pGL3-Basic vector (*300 RLU/mg protein). Luciferase activity for a full-length construct (pGL3-SCV) containing a 602 bp subregion of the BRCA1 promoter (7458 Figure 1 Diagram of the BRCA1 promoter region sequences used in the luciferase expression assays. Reporter constructs were named according to the presence and location of the three putative transcription factor binding motifs as indicated: Sp1 (S), CRE (C), and v-Myb (V).`-TV' constructs indicate that the CRE motif sequence has been altered (CG?TG). PCR primers used to amplify these sequences from genomic DNA are shown (arrows). Nucleotide numbers at the bottom of the ®gure refer to the GenBank sequence U37574 ) and possessed only the CRE and putative v-Myb elements. Considerably higher activity levels were observed with pGL3-CV (*95 000 RLU/mg protein). The ®nal construct, pGL3-V, encompassed the putative v-Myb element (7143 to +145), and showed the lowest level of activity at *19 000 RLU/mg protein, a level which is considerably higher than the pGL3-basic vector, yet less than onethird the amount seen with pGL3-CV. This decrease in expression seen with pGL3-V (relative to pGL3-CV) appears to coincide with the absence of the CRE motif. We also generated a luciferase reporter (pGL3-TV) in which we site-directed a mutation at the central CpG within a CREB recognition site that we have previously shown to be involved in CREB binding in gelshift assays (TTACGTCA?TTATGTCA; Mancini et al., 1999) . In all our experiments using these constructs (Tables 1b and 2 ), we found that the -TV constructs consistently displayed *30% of the luciferase activity that was seen with the -CV constructs, suggesting a role for an intact CRE in the expression of the BRCA1 reporter constructs. Similarly, in HCC1806 cells, *30% luciferase activity was seen with the transfected -TV construct in comparison with pGL3-CV transfections.
We further addressed the functionality of the CRE motif by generating luciferase reporters corresponding to the BRCA1 promoter subregions used by Suen and Goss (1999; 7247 to +38) . We transfected MCF7 and HCC1806 cell lines with truncated -CVr and -TVr reporter constructs (7247 to +38) in separate experiments performed in triplicate (Table 2 ). In both cell lines, the -CVr construct had 552% of the activity of the -CV construct. More profound eects were seen with these truncated -TVr constructs (MCF7: 16%; HCC1806: 4%). These results underscore the importance of an intact CRE in BRCA1 expression but also suggest that additional motif(s) in the 107 bps between +38 and +145 may also play a role in BRCA1 expression.
Effect of methylation on BRCA1 expression
To determine the eect of CpG methylation on luciferase expression, the constructs used in this study were methylated in vitro using SssI methylase (NEB). To control for the eects of the methylation procedure, aliquots of the constructs were`mock-methylated', in experiments where the vectors were incubated in the absence of the methylase and S-adenosyl methionine. The methylation status of the constructs was con®rmed prior to transfection by digestion with the methylationsensitive restriction enzyme HpaII (data not shown). Table 1 shows the eects of in vitro methylation on reporter activities. Similar luciferase activities were obtained with unmethylated and mock-methylated pGL3-Basic (approximately 300 RLU/mg protein). In experiments performed in triplicate, each of the constructs was methylated (or mock-methylated) and then transfected into MCF-7 cells so the eect of methylation on the transcriptional activity of the various promoter regions could be assessed. SssI treatment of the pGL3-Basic vector decreased luciferase activity to below the already modest levels seen with the unmethylated constructs. In all experiments, we determined that methylation had a profound eect on expression of the luciferase reporter constructs. Reducing luciferase expression levels to as low as 1% of the unmethylated or mock-methylated controls. SssI methylation of the full construct (pGL3-SCV) decreased activity driven by the BRCA1 element to a level that was 3% of the activity of the unmethylated pGL3-SCV. Similarly, the methylated pGL3-CV and pGL3-V constructs (containing the insert with the CRE and/or putative v-Myb elements alone) showed signi®cant decreases in activity relative to their unmethylated controls. In a separate experiment (Table 1b) , methylated or mock-methylated pGL3-CV or pGL3-TV constructs were transfected into MCF-7 cells. As described previously, methylation of both the pGL3-CV and pGL3-TV plasmids led to signi®cant decreases in reporter gene expression (495%) compared to their unmethylated counterparts. However, since these decreases could be due in part to methylation within the pGL3vector itself, several experiments were performed in which we ligated methylated -CV fragments into unmethylated pGL3 vectors. Thesè patch-methylated' constructs also showed a signi®cant (*50%) decrease in reporter gene expression in comparison to similarly prepared mock-methylated constructs; (data not shown). These results con®rm a signi®cant methylation eect that is focused within the BRCA1 promoter region and suggest that both mutational inactivation at critical transcription factor binding sites (such as the CRE) and/or aberrant DNA methylation at these sites may have diering but complementary roles in inactivating BRCA1 gene expression.
A series of plasmid mixing control experiments were also performed to determine whether the decreases in transcriptional activity shown were due to factors other than the methylation status of the plasmids. The pGL3-CV construct was transfected in 3 : 1, 1 : 1, and 1 : 3 ratios (methylated to mock-methylated) to control for transfection eciencies of the two constructs. A total of 1 mg of plasmid DNA was transfected in each case. Our results showed that when the methylated and mock-methylated plasmids are transfected together at a 1 : 1 ratio, the resulting level of expression is intermediate to those found when each plasmid was transfected alone. The results for the 3 : 1 and 1 : 3 experiments were as expected since expression decreased threefold and 1.2-fold, respectively (data not shown).
Analysis of the CRE motif
In previous studies performed by our laboratory, the eect of methylation on CREB binding was assessed by gelshift assays using methylated and unmethylated oligonucleotides analogous to the CRE binding motif within the BRCA1 promoter (Mancini et al., 1998) . We subsequently narrowed down the apparent methylation eect on CREB binding to a BRCA1 subregion containing two methylated CpGs located closely together, including one within the putative CRE at 7173. To determine which speci®c CpG in this subregion was sensitive to DNA methylation, gel mobility shift and competition assays were performed using MCF-7 nuclear extract and 10 5 c.p.m. (*1 pmole) of radiolabelled double-stranded oligonucleotides. In Figure 2 , two sets of oligonucleotides (spanning a region from 7179 to 7155) were used which diered in their methylation status at 7173 and 7166. Comparison of the bands present within lanes 2 and 7 ( Figure 2a) demonstrates that methylation at position 7173 (located within the CRE site) inhibits protein binding. The competition assays using excess unmethylated and methylated oligonucleotide (lanes 3 and 4) con®rm this eect. Conversely, lanes 2 and 7 in Figure 2b show that protein binding is not sensitive to CpG methylation at position 7166, a ®nding which is again con®rmed by the competition assays (lanes 3 and 4; lanes 8 and 9). For both gels, lanes 5 and 10 demonstrate the speci®city of CREB binding since the addition of excess cathepsin-D probe (CAP) does not compete away the band. Together, these results localize the methylation eect to one nucleotide in the BRCA1 CRE motif.
Recently, two reports addressed the functionality of this CRE motif but did not con®rm its identity by gelshift or supershift assays (Thakur and Croce, 1999; Suen and Goss, 1999) . We therefore performed experiments using several dierent oligonucleotide pairs, each of which contained the BRCA1 CRE motif. First, we used anti-CREB (Santa Cruz) and the previously described unmethylated 24 bp oligonucleotides in gelshifts with MCF-7 nuclear extracts ( Figure  3a ). We were able to supershift a DNA-protein complex recognizing the putative CRE motif (lane 5; Figure 3a ). Our experiments also reveal some of the complex DNA/protein interactions in the vicinity of the CRE motif. The competition assays in Figure 3a show that the unmethylated oligonucleotide competes eectively for the CREB protein complex, but in doing so appears to provide a low anity protein with access to the oligonucleotide template (*; lane 3). In contrast only low levels of this protein are seen in the presence of the excess methylated oligonucleotide (Figure 3a ; lane 4). This is possibly because the CREB protein complex cannot bind to the excess methylated oligonucleotide and thereby out competes this novel band for the labelled, unmethylated oligonucleotide. Interestingly, we con®rmed these results in lane 6 where our competitor (in excess) was an oligonucleotide speci®c for the transcription start site of the neuro®bromatosis type (NF1) promoter. This sequence contains a consensus CRE Figure 2 Gel mobility shift and competition assays to determine the speci®c methylation eect on CREB binding. These experiments used oligonucleotides that were methylated at nucleotide positions (A) 7173 (nt 1408) and (B) 7166 (nt 1415). In both ®gures, lanes 1 ± 5 show binding with labelled, unmethylated oligonucleotides and lanes 6 ± 10 with labelled, methylated oligonucleotides. Lanes 1 and 6 represent reactions performed in the absence of nuclear extract (`free'). Lanes 3 ± 5 and 8 ± 10: oligonucleotides incubated with the nuclear extracts followed by the addition of excess amounts of unlabelled, unmethylated oligonucleotides (lanes 3,8); unlabelled, methylated oligonucleotides (lanes 4,9); or an unlabelled, non-competing cathepsin D (CAP) oligonucleotides (lanes 5,10). The complexes were run on a 6% non-denaturing polyacrylamide gel and exposed to autoradiograph ®lm a b c Figure 3 Gel mobility shift, competition and supershift assays were performed using several dierent oligonucleotide pairs, each of which contained the BRCA1 CRE motif. (a) Gelshifts using the 24-mer oligonucleotide as described. Lane 1 shows free probe without cellular extract (free). Lane 2: MCF7 extract (NE) incubated with CRE 24-mer. Competition assays were performed with 250-fold excess unmethylated oligonucleotide (lane 3; Un), methylated oligonucleotide (lane 4; Meth) and an unmethylated oligonucleotide speci®c to the neuro®bromatosis type 1 (NF1) CRE region (lane 6; +Comp). Incubation with anti-CREB (Santa Cruz) resulted in a supershift of one of the bands in the CREB-oligonucleotide complex (lane 5; SS). (b) A supershift experiment using the 36 bp oligonucleotide speci®c to the BRCA1 positive regulatory region (PRR). Lane 1 shows free probe, while puri®ed CREB protein (Santa Cruz) binds to the BRCA1 PRR (lane 2). This complex can be supershifted with antibody speci®c to CREB (lane 3). (c) The 216 bp fragment was used as template in these gelshift assays. Unmethylated DNA template was used in lanes 1 ± 3; SssI methylated template was used in lanes 4,5. Lanes 1 and 4 show free template; lanes 2 and 5 show template complexed with MCF7 nuclear extract; lane 3 shows a supershift using anti-CRE antibody combined with the CRE-template complex (arrowhead). Dierences in the quantities of unbound template (unmethylated versus methylated) can be seen by comparing lanes 2 and 5 motif which we have recently identi®ed (Mancini et al., 1999) and like the excess BRCA1 competitor used in lane 3, the excess NF1 competitor titrates the higher anity CREB complex so that the lower anity protein can access the labelled CRE oligonucleotide. Next, supershift assays were performed using a 36 bp oligonucleotide speci®c to the BRCA1 positive regulatory region (PRR) which contains the putative CRE described by Thakur and Croce (1999) . As seen in Figure 3b , puri®ed CREB protein (Santa Cruz) binds to the BRCA1 PRR (lane 2) and this complex can be supershifted with antibody speci®c to CREB (lane 3). As well, we performed gel mobility shift experiments in which we incubated nuclear extract with the 216 bp fragment that contains the CRE (Figure 3c) . CREB protein causes a clear gel shift when the unmethylated fragment is used as the DNA template (lane 2). The inclusion of anti-CREB antibody results in a supershift of some components of the protein:DNA complex present in these bands (lane 3). Methylation of the 216 bp fragment has obvious eects, by signi®cantly decreasing the binding of CREB and other proteins in the complex to the methylated insert (compare lanes 2 and 5).
In vitro DNAse I footprinting assays
In vitro DNase I footprinting assays were also performed to con®rm the results obtained from the gel mobility shift assays. In these experiments, the probe consisted of a 216 bp fragment of the BRCA1 promoter which contains the CRE binding motif that was radioactively labelled, and in vitro methylated with SssI methylase. The methylated and unmethylated versions of the probe were incubated in the presence and absence of puri®ed CREB protein and subjected to digestion with DNase I.
As shown in Figure 4 , methylated or unmethylated 216 bp BRCA1 promoter fragments were incubated with DNase I, with (+) or without (7) puri®ed CREB protein and subsequently run on a 6% sequencing gel. Lanes 1 and 2 utilize the unmethylated 216 bp fragment from the BRCA1 promoter, whereas lanes 3 and 4 utilize a template methylated with SssI methylase. Lane 1 represents the unmethylated fragment incubated with DNase I alone and shows no footprint, while in lane 2, the addition of puri®ed CREB protein to the reaction mix depicts a clear footprint, encompassing the CRE motif as indicated by the boxed sequence to the left of the ®gure. In lane 3, the methylated fragment was incubated with DNase I alone and shows no footprint, while in contrast (lane 4) incubation of the methylated fragment with the puri®ed CREB protein and DNase I does not produce a footprint. These results corroborate the gel mobility shift analyses described earlier and con®rm the identity of a CRE motif in BRCA1. Furthermore, this CRE is highly sensitive to DNA methylation in vitro. This suggests that the site-and allele-speci®c BRCA1 methylation observed in breast and ovarian tumours by our group and by others (Thakur and Croce, 1999; Suen and Goss, 1999) In vitro footprinting assays. In vitro DNase I footprinting assays were performed using a 216 bp fragment of the BRCA1 promoter which contains the CRE binding motif. The SssI methylated and unmethylated versions of the probe were incubated in the presence (+) and absence (7) of puri®ed CREB protein and subjected to digestion with DNase I. Lanes 1 and 2 utilize the unmethylated 216 bp fragment from the BRCA1 promoter, whereas lanes 3 and 4 utilize a template methylated with SssI methylase. Lane 1 represents the unmethylated fragment incubated with DNAse I and without CREB protein (7) and shows a footprint extending between 7162 to 7182 upstream of the BRCA1 transcription start site that includes the intact CRE motif. In lane 2, the addition of puri®ed CREB protein (+) to the reaction mix depicts a clear footprint. In lane 3, the methylated fragment was incubated with DNase I and without CREB protein (7) and shows no footprint. As well, no footprint is seen in lane 4 when the methylated fragment is incubated with DNase I and puri®ed CREB protein
Discussion
The objectives of our present report were to characterize the functional eects of DNA methylation in the BRCA1 promoter using luciferase reporter constructs and to clarify the functional status of the BRCA1 CRE motif. CRE motifs are found within the promoters of many growth regulatory genes (Jones and Laird, 1999; Shattuck-Eidens et al., 1995) . CRE binding protein (CREB) forms part of a signalling pathway that initiates the cAMP-mediated activation of protein kinase and the subsequent phosphorylation and activation of the CREB protein (Thakur and Croce, 1999). Reporter constructs were generated which diered by the inclusion of three putative transcription factor motifs (Sp1, CRE and a putative V-myb; Jones and Laird, 1999; Rice et al., 1998; Maesawa et al., 1996) . Each of these constructs were expressed in MCF-7 cells, yet did so with diering activities. The highest activity was seen with pGL3-CV, which gave results that were 300-fold greater than the basic pGL3 vector, while a decrease in pGL3-V expression (relative to pGL3-CV) coincided with the absence of the CRE. Transfections of the pGL3-CV reporter into MCF7 and HCC1806 cells (Table 2) showed that the introduction of the C?T mutation at the CRE motif reduced luciferase activity from the pGL3-TV construct by 70% relative to pGL3-CV.
We also transfected the truncated pGL3-CVr and pGL3-TVr reporter constructs in separate experiments and found signi®cant decreases in comparison with the full-length pGL3-CV and pGL3-TV constructs. Luciferase activities following transfection with pGL3-TVr were even more signi®cantly aected (4% of pGL3-CV). These results suggest that the CRE alone is not sucient for optimal BRCA1 transcription, and that other as yet unidenti®ed transcription factor motifs in the 107 bp subregion between +38 and +145 may also contribute to BRCA1 expression. We are presently undertaking experiments to clarify what appears to be a more complex mechanism involved in regulating BRCA1 expression than was originally suspected from previous work.
In our previous study we assessed the apparent methylation eect on CREB binding in a BRCA1 subregion containing two methylated CpGs located closely together, including one within the putative CRE at position 7173 (Mancini et al., 1998) . In the present study, gel mobility shift and competition assays determined that methylation at position 7173 speci®-cally inhibits protein binding (Figure 2b) . Conversely, protein binding is not sensitive to CpG methylation at position 7166. Competition assays using excess unmethylated and methylated oligonucleotides con®rm this eect, localizing the methylation eect to the CpG at 7173 within the BRCA1 CRE motif.
We have conclusively identi®ed CREB binding at the BRCA1 CRE using extracts from MCF7 cells and from four other breast carcinoma cell lines (data not shown). We showed that a speci®c protein complex from MCF-7 cell extracts would recognize the putative CRE in gelshift assays using the 24 bp oligonucleotides ( Figure  3a ). Furthermore, we were able to supershift the DNAprotein complex recognizing the putative CRE motif using CREB-speci®c antibody and we were also able to compete away CREB binding using excess unmethylated oligonucleotide. Conversely, CREB binding was not competed away by excess methylated oligonucleotide, again con®rming the methylation sensitivity of the BRCA1 CRE seen in Figures 2 and 3 . We also con®rmed these results in experiments where the excess competitor was an unlabelled CRE-containing oligonucleotide speci®c for the transcription start site of the neuro®bromatosis type (NF1) promoter (Mancini et al., 1999) , which titrates away the higher anity BRCA1 CREB complex (Figure 3a) .
Supershift assays using a 36 bp oligonucleotide speci®c to the BRCA1 PRR showed that puri®ed CREB protein binds to the BRCA1 PRR (lane 2) and that this complex can be supershifted with CREBspeci®c antibody (Figure 3b) . A clear supershift was also seen when we incubated puri®ed CREB protein with an unmethylated 216 bp fragment (Figure 3b ). The CREB antibody supershifts most of the protein: DNA complex present in these bands. This eect is reversed in experiments where the methylated fragment interferes with CREB binding. In vitro methylation with SssI methylase signi®cantly decreased expression of the luciferase reporter constructs by up to 150-fold. Our results using methylated and unmethylated pGL3-Basic show that only a small proportion of these signi®cant decreases in reporter activity appeared to be due to in vitro methylation of CpG sites within the pGL3-Basic vector itself. Clearly, an intact, accessible CRE is important for optimal expression of these BRCA1 reporter constructs.
Footprinting assays were also performed using methylated and unmethylated versions of the 216 bp BRCA1 promoter fragment (Figure 4 ). This footprint encompasses the region between 7162 to 7182 upstream of the BRCA1 transcription start site, and extends beyond the intact CRE motif. SssI methylation of this 216 bp template prior to incubation with puri®ed CREB protein and Dnase I treatment abolishes the footprint (Figure 4) . These results corroborate the gel mobility shift analyses described earlier, con®rm the identity of a CRE motif in BRCA1 and underscore the apparent methylation sensitivity of the CRE. This protected sequence includes the 3' boundary of the EcoRI ± MspI fragment that Suen and Goss (1999) used in their experiments. In fact, our analysis shows this EcoRI ± MspI fragment ends only 2 bp 3' to the CRE consensus sequence and is within the previously described minimum promoter region (Xu et al., 1997) and PRR (Thakur and Croce, 1999) . Suen and Goss (1999) were unable to show CREB binding using this EcoRI ± MspI fragment. Our data suggest that this EcoRI ± MspI fragment represents an incomplete template which cannot support binding of the CREB complex, thus preventing the initiation of transcription from the CAT reporter constructs used by Suen and Goss (1999) .
Together, our results provide evidence that DNA methylation exerts a suppressive eect on BRCA1 expression. This methylation eect includes, but is not restricted to the CRE. Similarly, Magdinier et al. (2000) showed that partial methylation of a luciferase vector containing part of the 5' end of BRCA1 mimics methylation patterns observed in somatic cells and induced a MeCP2-dependent repression of transcriptional activity. While it is clear that the CRE is involved in BRCA1 expression, other sites within the PRR polypyrimidine tract immediately 5' to the CRE are likely important for BRCA1 expression (Atlas et al., 2000; Thakur and Croce, 1999; Suen and Goss, 1999; Xu et al., 1997) . Furthermore, a conserved CCAAT box located approximately 20 bp downstream of the CRE also represents a potential BRCA1 control region (Xu et al., 1997) . It is interesting to note that the methylation insensitive CpG (Figure 3 ) at position 7166 is located within a HpaII site (CCGG). Our results show that while restriction enzymes are useful for detecting the presence of aberrant promoter methylation patterns, the detection of HpaII insensitivity at a speci®c CpG does not necessarily mean methylation at that site has functional signi®cance. Instead, the mechanisms responsible for aberrant methylation may indiscriminately methylate all accessible CpGs within a CpG island, while the functional consequences of such aberrant methylation may be limited to a few critical factor binding sites such as the CRE which act to recruit other transcription activators into a functional complex.
Our data, in combination with previous evidence of aberrant methylation within the BRCA1 promoter in various tumours point toward the contribution of epimutations in the down-regulation of tumour suppressor genes leading to tumorigenesis (Rice et al., 1998 Jones and Laird, 1999; Mancini et al., 1998) . The molecular mechanisms responsible for establishing and maintaining such appropriate patterns of DNA methylation in cells are partially understood, although the complete role for aberrant methylation at speci®c loci in tumour progression is still unclear. For example, it is not known whether altered DNA methylation within the BRCA1 promoter represents a single epigenetic event limited to that particular locus, or whether it is a signpost of a more extensive global alteration in methylation patterns. At least two scenarios can account for the involvement of BRCA1 in this process. A gene-speci®c model relies on BRCA1 as a caretaker gene with a DNA repair role (Rodenhiser et al., 1996 . The silencing of one BRCA1 allele creates genomic instability within the cell which predisposes that cell to tumour formation. The primary event for BRCA1 inactivation could include either aberrant methylation or mutations at boundary sequences (i.e. Sp1 motifs) which constitutively maintain the methylation-free promoter regions (Rice et al., 1998; Okuse et al., 1997) .
The second model involves altered global methylation patterns and relies on a primary event that modi®es methylation at multiple genes throughout the genome. A global shift in methylation patterns in promoter regions, perhaps due to over expression of DNA methyltransferases could have profound consequences to an array of genes (such as BRCA1, ER and PR) that are normally expressed in the host tissue. It is interesting that at least two groups have shown aberrant BRCA1 methylation in sporadic breast tumours that were also classi®ed as ER and/or PR negative (Catteau et al., 1999; Dobrovic and Simpfendorfer, 1997) . Although the methylation status within the ER and PR promoters was not determined in these studies, it is a tantalizing possibility that multiple epigenetic events may occur, particularly since aberrant ER methylation has been reported by a number of groups in breast and ovarian tissues. In this model, aberrant methylation would have a speci®c eect in downregulating each of these genes, but it would be the cumulative eect of the primary methylation errors throughout the entire genome which would provide a selective advantage to individual cells, leading to tumour formation.
Whether such methylation defects are limited to a single gene or encompass many loci, the functional consequences of aberrant promoter methylation to tumorigenesis would still be signi®cant. Equally important is the fact that each of these models could account for the disparity between hereditary breast cancer (where BRCA1 or BRCA2 mutations are frequent) and sporadic cases of this disease, where BRCA1 (or BRCA2) mutations appear to be infrequent, if not absent. Clearly, the transcriptional consequences of aberrant DNA methylation, along with the multiple mutational events that can occur in a variety of essential genes, paint a complex picture where both genetic and epigenetic alterations in gene expression contribute to tumour formation.
Materials and methods
Cell culture
MCF-7 breast carcinoma cells were grown in 6-well plates in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with L-glutamine (200 mM), HEPES (10 mM), penicillin (100 mg/ml), streptomycin (100 mg/ml), and 10% foetal bovine serum. These cells were maintained in a humidi®ed incubator at 378C with 5% CO 2 .
Plasmid construction
DNA templates for the reporter constructs were generated by PCR using primers designed with XhoI and HindIII restriction sites at their 5' ends. The PCR primers used in these ampli®cation reactions were: DR225: 5'-GGCTCG-AGACCTTTCATTCCGCAACG-3'; DR226: 5'-GGGCTC-GAGTAGAGGCTAGAGGGCAGG-3'; DR227: 5'-GGC-TCGAGCCCCGAGAGACGCTTGGC-3'; DR228: 5'-CCA-AGCTTGCCACGGAAACCAAGGGGC-3'; DR229: 5'-CC-AAGCTTTCCCGGGACTCTACTAC-3'; DR1618r: 5'-CCA-AGCTTCTCAGCGAGCTCACGCCGCGC-3'.
A proofreading Taq (Platinum Taq; Gibco-BRL) was used to minimize the occurrence of ampli®cation errors. A set of overlapping fragments of the BRCA1 promoter region terminating at position +145 (nucleotide 1725; GenBank sequence U37574) were ampli®ed. Each fragment diered depending on the presence of putative Sp1 (S), CRE (C) and v-Myb (V) transcription elements (Figure 1) . In some experiments, truncated fragments were generated using primer DR1618r which terminated at position +38 (nt 1618). Each of the PCR fragments were subsequently ligated into the pCRII TOPO-TA cloning vector (Invitrogen), transformed and then screened. Clones that were positive for the BRCA1 fragments were then puri®ed by alkaline lysis and sequenced to ensure sequence ®delity (Mancini et al., 1998) . The fragments were then excised from pCRII by digestion with XhoI and HindIII and were gel-puri®ed. These BRCA1 promoter subregions were then ligated in a 3 : 1 molar ratio into the pGL3-Basic luciferase reporter vector (Promega) for 2 h at room temperature. Ligations were subsequently transformed and the resulting clones were screened for the presence of insert, puri®ed by alkaline lysis and re-sequenced.
Plasmid methylation
Aliquots of each reporter construct (20 mg) were methylated using 8 units of SssI methylase (NEB) at 378C for 8 ± 13 h, with subsequent inactivation of enzyme at 608C for 20 min. Mock-methylation reactions were also performed in the absence of the methylase enzyme and S-adenosyl methionine. The methylated and mock-methylated constructs were puri®ed using Wizard DNA puri®cation columns (Promega) and the methylation status of each construct was determined by HpaII digestion.
Mammalian cell transfection
10
5 MCF-7 or HCC1806 cells (Gazdar et al., 1998) were seeded in each well of 6-well 35 mm 2 tissue culture plates. Transfections were carried out in triplicate (three separate transfections for each experimental condition, performed on the same day) using 4 ml of lipofectamine reagent (Gibco-BRL) and 1 mg of either the methylated or mock-methylated plasmids. Cells were harvested 48 h after transfection and cell lysates were assayed for luciferase activity using the protocols from the Promega luciferase kit. Total protein was determined by Bradford assay, while activities were standardized relative to pGL3-Basic vector controls. We con®rmed equivalent transfection eciencies for the pGL3 vectors by cotransfecting with the pSV-b galactosidase vector and determining b-Gal activities in the cell lysates (data not shown).
Site-directed mutagenesis experiments
We performed site-directed mutagenesis at the CRE, changing the central CpG dinucleotide to a TpG dinucleotide (TGACGTCA?TGATGTCA). We ampli®ed the region containing both the CRE and putative v-Myb elements (pGL3-CV; DR227 and DR229). A second smaller fragment was then ampli®ed using primer DR229 and DR290 containing a single base pair C?T alteration within the CRE (DR290: 5'-CTCTTCCGTCTCTTTCCTTTTATGT-CATCCGGGGGC-3'). The two PCR products were combined and allowed to anneal and elongate for 20 cycles without addition of primers. A further PCR round (30 cycles) was carried out after addition of primers DR227 and DR229. This PCR product was ligated into pGL3 luciferase reporter vector, the presence of the mutation was veri®ed by sequencing, and the vector was transfected as previously described.
Gel mobility shift assays
Gel mobility shift assays were designed to con®rm speci®c binding of the CREB protein to this region of the BRCA1 promoter, as well as to establish that methylation of this region interferes with CREB binding. Oligonucleotides of dierent sizes (24 bp, 36 bp, and 216 bp) were used which contained the putative CRE element located at position 7173 (nt 1408 in the GenBank sequence U37574; Mancini et al., 1998) . Methylated versions of these oligonucleotides (where CpGs at positions 7173 (nt 1408) and/or 7166 (nt 1415) were methylated) were synthesized on a Beckman Oligo 1000M DNA synthesizer using methylated phosphoramidites (Glen Research; Sterling, VA, USA). In one experiment, the site-speci®c eect of methylation on CREB binding was evaluated using the 24 bp oligonucleotide and methylating the CpG either at position 7173 or 7166. In several experiments, gelshifts used a 216 bp CRE fragment extending from position 7247 to 730. Nuclear extracts were prepared from MCF-7 cells as previously described (Mancini et al., 1998) and these extracts were stored at 7808C until use. Several experiments utilized puri®ed CREB protein (Santa Cruz) in place of nuclear extracts and in some cases, the oligonucleotides used were methylated with SssI methylase. In all experiments, double-stranded oligonucleotides were end labelled with g-32 P-ATP (Amersham; 6000 Ci/mmol, 1 Ci=37 GBq) using T4 polynucleotide kinase (Mancini et al., 1998) . Electrophoresis and ®lm imaging was performed as previously described (Mancini et al., 1998) .
DNase I footprinting assay
Plasmids were constructed by ligating a PCR-generated 216 bp fragment of the BRCA1 promoter (containing the CRE binding site) to the TA cloning vector (TA cloning system; Invitrogen, San Diego, CA, USA). Approximately 5 mg of plasmid DNA was subsequently linearized by digestion with XhoI enzyme (378C for 6 h), ethanol precipitated and dissolved in 5 ml distilled H 2 O. The resulting recessed 3'-end was then ®lled in with Klenow (60 mCi of [a-32 P] dCTP, 13.3 mM unlabelled dNTPs; 10 min at room temperature) in the absence of unlabelled dCTP. Next, 4 mM of unlabelled dCTP was added to the reaction mixture prior to puri®cation on a G-50 spin column (Pharmacia). The eluate was subsequently precipitated with ethanol and the insert was released by digestion with the second enzyme (HindIII) at 378C for 6 h (Archer et al., 1990) .
The digest was run on a polyacrylamide gel, the fragment containing the released insert excised, and the DNA eluted by crush/elute at 378C overnight. The eluate was precipitated with ethanol and dissolved in 10 mM Tris-0.1 mM EDTA. Aliquots of the labelled probe were then methylated and mock methylated, with and without SssI methylase, respectively, according to the manufacturer's instructions (NEB). Approximately 10 000 c.p.m. of this DNA was used as a probe for each footprinting reaction, in the presence of poly (dI:dC), footprinting buer (250 mM HEPES pH 7.6, 50 mM MgCl 2 , 340 mM KCl), and 1 mg of puri®ed CREB protein (Santa Cruz).
The footprinting reaction was incubated at room temperature for 15 min. Next, DNase I was added to the reaction (Worthington, 7.5 units/ml, diluted 1 : 75) and incubated on ice for 5 min. To stop the reaction, 4 mg/ml salmon sperm DNA (ss DNA), 10 mg/ml proteinase K, and 5 ml stop buer (20 mM Tris-HCl, 20 mM EDTA, 250 mM NaCl, and 0.5% SDS) were added to the reaction mixture. The footprinting reaction was then incubated at 458C for 30 ± 60 min. Phenol: Chloroform extraction was performed and the DNA was then precipitated with absolute ethanol. The samples were then separated on a 6% sequencing gel and subsequently exposed to autoradiographic ®lm.
Generation of a G/A ladder to determine the position of protein binding within a particular sequence was achieved by Maxam-Gilbert sequencing. First, approximately 20 000 c.p.m. of probe was lyophilized with 1 mg of ssDNA for 10 min. Next, 2.5 ml of 2% formic acid (freshly diluted in water) was added, and the mixture incubated at 378C for 10 min. The reaction was quenched in dry ice/ethanol and lyophilized for at least 30 min, resuspended in 100 ml of 1 M (10%) piperidine (freshly diluted in water), and incubated at 908C for 30 min. The reaction was again quenched in dry ice/ ethanol and lyophilized for at least 90 min. Subsequently, the sample was resuspended in 40 ml of water, lyophilized for 10 min and resuspended in 10 ml formamide marker dye.
